ID

18257

Descripción

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT00134563

Link

https://clinicaltrials.gov/show/NCT00134563

Palabras clave

Versiones (1)
  1. 27/10/16 27/10/16 -
Subido en

27 de octubre de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Multiple Sclerosis NCT00134563

Inglés

Eligibility Multiple Sclerosis NCT00134563

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
multiple sclerosis [ms] subject who was ambulatory (edss of ≤ 5.5)
Descripción

Multiple Sclerosis | Outpatient | EDSS

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0026769
UMLS CUI [2]
C0029921
UMLS CUI [3]
C0451246
exhibiting a relapsing clinical course, with or without progression (relapsing remitting, secondary progressive or progressive relapsing);
Descripción

Relapsing course Clinical | Disease Progression | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Progressive Relapsing

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0205336
UMLS CUI [1,2]
C0205210
UMLS CUI [2]
C0242656
UMLS CUI [3]
C0751967
UMLS CUI [4]
C0751965
UMLS CUI [5]
C0393666
meeting mcdonald's criteria for ms diagnosis;
Descripción

Multiple Sclerosis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0026769
experienced at least 1 relapse over the 1 year preceding the trial or at least 2 relapses over the 2 years preceding the trial;
Descripción

Relapse Quantity Period

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0035020
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C1948053
no relapse onset in the preceding 60 days prior to randomization;
Descripción

Relapse Onset

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0035020
UMLS CUI [1,2]
C0332162
clinically stable during the 30 days prior to randomization, without adrenocorticotrophic hormone [acth] or systemic steroid treatment.
Descripción

Stable status Clinical | Corticotropin | systemic steroids

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0205360
UMLS CUI [1,2]
C0205210
UMLS CUI [2]
C0001655
UMLS CUI [3]
C2825233
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease;
Descripción

Cardiovascular Disease Relevant Clinical | Liver disease Relevant Clinical | nervous system disorder Relevant Clinical | Endocrine System Disease Relevant Clinical | Systemic disease Major

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C2347946
UMLS CUI [1,3]
C0205210
UMLS CUI [2,1]
C0023895
UMLS CUI [2,2]
C2347946
UMLS CUI [2,3]
C0205210
UMLS CUI [3,1]
C0027765
UMLS CUI [3,2]
C2347946
UMLS CUI [3,3]
C0205210
UMLS CUI [4,1]
C0014130
UMLS CUI [4,2]
C2347946
UMLS CUI [4,3]
C0205210
UMLS CUI [5,1]
C0442893
UMLS CUI [5,2]
C0205164
significantly impaired bone marrow function;
Descripción

Bone Marrow function Impaired Significant

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [1,3]
C0221099
UMLS CUI [1,4]
C0750502
pregnant or nursing woman;
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
alcohol or drug abuse;
Descripción

Substance Use Disorders

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0038586
use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;
Descripción

Cladribine | Mitoxantrone | Immunosuppressive Agents | Azathioprine | Cyclophosphamide | Cyclosporine | Methotrexate | MYCOPHENOLATE

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0092801
UMLS CUI [2]
C0026259
UMLS CUI [3]
C0021081
UMLS CUI [4]
C0004482
UMLS CUI [5]
C0010583
UMLS CUI [6]
C0010592
UMLS CUI [7]
C0025677
UMLS CUI [8]
C0883242
any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study;
Descripción

Condition Preventing Protocol Compliance

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C1292733
UMLS CUI [1,3]
C0525058
Volver a la parte superior de la página

Similar models

Eligibility Multiple Sclerosis NCT00134563

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Sclerosis | Outpatient | EDSS
Item
multiple sclerosis [ms] subject who was ambulatory (edss of ≤ 5.5)
boolean
C0026769 (UMLS CUI [1])
C0029921 (UMLS CUI [2])
C0451246 (UMLS CUI [3])
Relapsing course Clinical | Disease Progression | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Progressive Relapsing
Item
exhibiting a relapsing clinical course, with or without progression (relapsing remitting, secondary progressive or progressive relapsing);
boolean
C0205336 (UMLS CUI [1,1])
C0205210 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
C0751967 (UMLS CUI [3])
C0751965 (UMLS CUI [4])
C0393666 (UMLS CUI [5])
Multiple Sclerosis
Item
meeting mcdonald's criteria for ms diagnosis;
boolean
C0026769 (UMLS CUI [1])
Relapse Quantity Period
Item
experienced at least 1 relapse over the 1 year preceding the trial or at least 2 relapses over the 2 years preceding the trial;
boolean
C0035020 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1948053 (UMLS CUI [1,3])
Relapse Onset
Item
no relapse onset in the preceding 60 days prior to randomization;
boolean
C0035020 (UMLS CUI [1,1])
C0332162 (UMLS CUI [1,2])
Stable status Clinical | Corticotropin | systemic steroids
Item
clinically stable during the 30 days prior to randomization, without adrenocorticotrophic hormone [acth] or systemic steroid treatment.
boolean
C0205360 (UMLS CUI [1,1])
C0205210 (UMLS CUI [1,2])
C0001655 (UMLS CUI [2])
C2825233 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Cardiovascular Disease Relevant Clinical | Liver disease Relevant Clinical | nervous system disorder Relevant Clinical | Endocrine System Disease Relevant Clinical | Systemic disease Major
Item
clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease;
boolean
C0007222 (UMLS CUI [1,1])
C2347946 (UMLS CUI [1,2])
C0205210 (UMLS CUI [1,3])
C0023895 (UMLS CUI [2,1])
C2347946 (UMLS CUI [2,2])
C0205210 (UMLS CUI [2,3])
C0027765 (UMLS CUI [3,1])
C2347946 (UMLS CUI [3,2])
C0205210 (UMLS CUI [3,3])
C0014130 (UMLS CUI [4,1])
C2347946 (UMLS CUI [4,2])
C0205210 (UMLS CUI [4,3])
C0442893 (UMLS CUI [5,1])
C0205164 (UMLS CUI [5,2])
Bone Marrow function Impaired Significant
Item
significantly impaired bone marrow function;
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0221099 (UMLS CUI [1,3])
C0750502 (UMLS CUI [1,4])
Pregnancy | Breast Feeding
Item
pregnant or nursing woman;
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Substance Use Disorders
Item
alcohol or drug abuse;
boolean
C0038586 (UMLS CUI [1])
Cladribine | Mitoxantrone | Immunosuppressive Agents | Azathioprine | Cyclophosphamide | Cyclosporine | Methotrexate | MYCOPHENOLATE
Item
use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;
boolean
C0092801 (UMLS CUI [1])
C0026259 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
C0004482 (UMLS CUI [4])
C0010583 (UMLS CUI [5])
C0010592 (UMLS CUI [6])
C0025677 (UMLS CUI [7])
C0883242 (UMLS CUI [8])
Condition Preventing Protocol Compliance
Item
any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study;
boolean
C0348080 (UMLS CUI [1,1])
C1292733 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial